Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Healthcare Cannabis Psychedelics
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Core One Labs Inc
Bullboard Posts
User Avatar Image
(29)
•••
Post by bullman246on Sep 19, 2018 4:37pm
157 Views
Post# 28650645

Just Spoke To Phil Today - Another Problem?

Just Spoke To Phil Today - Another Problem?I spoke to Phil today. The one issue that most disturbed me was his comment that LDS has to tread very carefully, because of banking laws regarding Canadian cannabis companies like LDS, operating and selling in the U.S.

I also understood Phil to say that the banking laws might get even more restrictive for LDS. Strangely, when asked about the lack of news releases, Phil said that all news releases will now go through LDS' subsidiary - CSPA Group, instread of LDS. How then will LDS shareholders receive timely news events?

Do banking regulations pose a risk to LDS? How many other Canadian cannabis companies are selling in the US?  Are they equally concerned?

He confirmed that LDS is hoping for $0.5-$1 million in revenue in September. A far cry from the earlier estimate of $14 million/month for 2,000 liters of production in Sept X $7,000/liter. He indicated that clean biomass supply is and will always be a problem.

They just continue extending goals, and making delays and excuses. What a loser stock.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities